Generic Drugs Had Largest Quarterly AMP Fluctuations In OIG Study
[June 14 Editor's Note: This is an updated version of a story originally published with the headline "Single-Source Drugs Show Greatest Overall AMP Fluctuation Between Quarters."]
You may also be interested in...
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.
Phase III data for Affymax/Takeda's anemia drug for chronic kidney failure signals potential regulatory hurdles in non-dialysis use.
Elagolix could be the first oral drug approved for endometriosis that does not have severe side effects.